QUEST DIAGNOSTICS INC
Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.
Quest Diagnostics (DGX) shares rose 3.9% today, driven by positive investor sentiment around its consumer health initiatives, including integration with the Apple Health app. Management's upbeat commentary at a recent conference and strong Q2 performance, with double-digit revenue growth and raised 2026 guidance, also contributed. Analysts have recently increased price targets.
Quest Diagnostics (DGX) is launching direct-to-consumer lab test integration with Apple Health, allowing U.S. users to order tests and view results. The partnership aims to enhance preventive testing access for iPhone users. DGX has a $26.0b market cap and offers a $119 panel covering 50+ biomarkers. Success depends on user adoption and repeat testing. The company will likely disclose adoption data in future updates.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning DGX (QUEST DIAGNOSTICS INC). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent DGX coverage spans technology, insider activity and earnings.
In the last 30 days, DGX insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($7.9M). The most active reporter was PREVOZNIK MICHAEL E, SVP & General Counsel, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Robust earnings beat supports continued buying pressure.
The Apple Health partnership could expand consumer lab testing, supporting near‑term upside.
The rollout could generate recurring revenue from consumer testing and expand Quest's addressable market.
Potential modest revenue boost from consumer lab testing channel.
Insider sale may signal reduced confidence, but size is modest for a large cap.
AlphAI scores every news story that mentions DGX with an AI model for sentiment and relevance, and aggregates insider trades from QUEST DIAGNOSTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.
3 min readQuest Diagnostics (DGX) shares rose 3.9% today, driven by positive investor sentiment around its consumer health initiatives, including integration with the Apple Health app. Management's upbeat commentary at a recent conference and strong Q2 performance, with double-digit revenue growth and raised 2026 guidance, also contributed. Analysts have recently increased price targets.
1 min readQuest Diagnostics (DGX) is launching direct-to-consumer lab test integration with Apple Health, allowing U.S. users to order tests and view results. The partnership aims to enhance preventive testing access for iPhone users. DGX has a $26.0b market cap and offers a $119 panel covering 50+ biomarkers. Success depends on user adoption and repeat testing. The company will likely disclose adoption data in future updates.
2 min readQuest Diagnostics (DGX) announced a partnership with Apple to offer lab testing through the Apple Health app. Users can purchase a panel of 50+ biomarkers for $119, with results appearing in the app. The service aims to promote preventive health and is set to launch later this year in the U.S.
2 min readDavis J. E. (CEO and President) sold 10,000 shares of QUEST DIAGNOSTICS INC (DGX) at $242.72 ($2.43M total) on 2026-09-01 under a Rule 10b5-1 trading plan.
1 min readQuest Diagnostics (DGX) has partnered with Renalytix for kidney testing, adding to recent Alzheimer's and wellness test launches. DGX stock has seen a 90-day return of 21.97% and a 1-year return of 34.51%, despite recent declines. The company's fair value is estimated at $245.87, with potential risks including reimbursement pressures and rising costs.
2 min readPREVOZNIK MICHAEL E (SVP & General Counsel) sold 22,677 shares of QUEST DIAGNOSTICS INC (DGX) at an average of $243.11 ($242.88–$244.51, $5.51M total) across 3 trades on 2026-08-28 under a Rule 10b5-1 trading plan.
1 min readHumanity Health and Quest Diagnostics (DGX) launched a biological age test in the US via Quest’s platform. The $29 add-on uses biomarkers from routine blood tests to estimate biological age and track changes over time. Developed with Imperial College London, the model was validated on over 306,000 participants. The service is available at Quest’s 2,000 service centers.
2 min readThe FDA cleared a new blood test, Elecsys pTau217, developed by Roche and Eli Lilly, for evaluating Alzheimer's disease in people 55+. The test measures phosphorylated tau 217, a biomarker linked to amyloid pathology. It is designed to support diagnostic assessments but not replace full medical evaluations. Roche and Lilly aim to make the test accessible in primary care settings, potentially improving early diagnosis and treatment planning.
2 min readQuest Diagnostics will offer Roche’s FDA-cleared pTau217 blood test for Alzheimer’s assessment in Q4 2026, along with its own multi-biomarker panel in 2027. The tests aim to improve diagnosis accuracy and reduce indeterminate results, aligning with Alzheimer’s Association guidelines.
2 min read
